Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Naples – page 38

1 221 clinical trials in Naples, Italy across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Naples at a glance
1 221
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 221 trials in Naples

Open in trial search

Small cell lung cancer extensive stage

Recruiting

Study on Durvalumab with Carboplatin or Cisplatin and Etoposide for First-Line Treatment in Patients with Extensive Stage Extrapulmonary Small Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Malignant melanoma

Recruiting

Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Chronic cutaneous lupus erythematosus+2

Recruiting

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Schizoaffective disorder+2

Recruiting

Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amisulpride
  • Sponsor:Universitair Medisch Centrum Utrecht

Lymphangioma

Recruiting

Study on Alpelisib for Treating Lymphatic Malformations in Patients with PIK3CA Mutation

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Bipolar disorder

Recruiting

Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Citalopram
  • Sponsor:Universitair Medisch Centrum Utrecht

Crohn's disease

Recruiting

Study on Crohn's Disease: Evaluating Risankizumab's Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Major depression

Recruiting

Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Agomelatine
  • Sponsor:Universitair Medisch Centrum Utrecht

Gastrooesophageal cancer+1

Recruiting

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Fondazione GONO G.I.

Diabetic foot infection

Recruiting

Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Micurx Pharmaceuticals Inc.

Acute lymphocytic leukaemia

Recruiting

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Metastatic malignant melanoma

Recruiting

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Naples

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on pulmonary conditions including innovative treatments for idiopathic pulmonary fibrosis and COPD. Studies evaluate new medications like tezepelumab and investigate respiratory syncytial virus vaccines for older adults.

  • Idiopathic Pulmonary Fibrosis
  • COPD Management
  • RSV Prevention

Clinical trials aim to improve lung function and reduce disease progression in patients with chronic respiratory conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with emphasis on targeted therapies and immunological approaches. Investigations include treatments for colorectal, gastric, and lung cancers.

  • Breast Cancer Prevention
  • Gastrointestinal Cancers
  • Advanced Solid Tumors

Novel therapeutic combinations and precision medicine approaches are being evaluated for improved patient outcomes.

03 Chronic Diseases

Studies addressing kidney disease, cardiovascular conditions, and neurological disorders. Innovative treatments for Parkinson's disease and end-stage kidney disease are under investigation.

  • Kidney Disease Management
  • Heart Failure Prevention
  • Neurological Disorders

Research focuses on developing safer and more effective treatments for chronic conditions affecting quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.